ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR/ARHP Annual Meeting 2017

Abstract Number: 224

Patterns of Methotrexate Use in African Countries with Low Versus Medium/High Human Development Index: Preliminary Results of Semi-Structured Interviews

Carol A Hitchon1, Yan Liu2, Steven Shi3, Girish M Mody4, Candace H. Feldman5, Michael Weinblatt6 and Ines Colmegna7, 1Internal Medicine, University of Manitoba, Winnipeg, MB, Canada, 2McGill University, Montreal, QC, Canada, 3University de Montreal, Montreal, QC, Canada, 4Dept of Rheumatology, University of Kwa Zulu-Natal, Durban, South Africa, 5Brigham and Women’s Hospital, Division of Rheumatology, Immunology and Allergy, Boston, MA, 6Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 7Division of Rheumatology, Department of Medicine, Division of Experimental Medicine, McGill University, Montreal, Quebec, Canada, Montreal, QC, Canada

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR/ARHP Annual Meeting 2017

Date of first publication: September 18, 2017

Keywords: Economics, health disparities and methotrexate (MTX), ILAR

Session Information

Date: Sunday, November 5, 2017

Title: Healthcare Disparities in Rheumatology Poster

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Methotrexate (MTX) is standard therapy for rheumatoid arthritis (RA) and also used to treat other rheumatic diseases. Existing guidelines for RA treatment/ MTX use did not contemplate the realities of resource limited countries. We aimed to understand MTX use patterns and barriers in African countries to inform the development of culturally appropriate guidelines.

Methods: We identified African physicians (MDs) from countries classified as low Human Development Index (LHDI) and medium/high HDI (MHDI) by the United Nations Development Programme and who self-identified as MTX prescribers.  Each MD participated in a 45 minute semi-structured interview by phone in either English or French regarding their MTX practices.

Results: 29 MDs (23 rheumatologists; 6 internists) from 29 African countries were interviewed (17 LHDI; 12 MHDI) representing a population of 1,000.4 million; (LHDI 673.8 million; MHDI 326.6 million). The median (range) of rheumatologists/ million population in these countries was only 0.17 (0-9.4).  LHDI countries had significantly fewer rheumatologists/ million population than MHDI (0.1 (0-0.66) vs 1.1(0-9.43) p=0.004).  MTX was prescribed by non-rheumatologists in 93% LHDI and 67% MHDI countries. Most MDs practised in capital cities and served adult patients. 88% LHDI and 67% MHDI MDs also provided pediatric care. The main indication for MTX use was RA with connective tissue diseases and psoriatic arthritis as secondary indications. Prior to prescribing MTX, most MDs (97%) evaluated patients for pulmonary, hepatic and renal dysfunction and excluded cytopenias. Screening was performed for TB (with CXR) by 62%, HIV by 55% and Hepatitis B/C by 52%.  Pregnancy screening was usually by patient self-report (86%). Discussing alcohol consumption was considered pertinent to the local consumption by 42% of MDs. MTX dosing was similar between LDHI and MDHI countries, and usually given with folate (83%). Only 55% of countries had parenteral MTX.  55% of MDs reported barriers to MTX use due to drug availability or costs.  Compared to MHDI countries, LHDI countries were more likely to have an inconsistent MTX supply throughout the year (82% LHDI vs 42% MHDI (p=0.05) and less likely to have MTX available in the hospital pharmacy (35% LHDI vs 83% MHDI; p=0.02). Major contributors to MTX non-adherence included drug cost or availability (85%), lack of prescribers (15%) and patients’ beliefs/education/tolerance (37%).

Conclusion: The challenges of treating RA patients in African countries with low HDIs are unique.  Costs of medical care and drugs, limited subspecialist availability, patient specific beliefs, and lack of MTX are significant challenges faced by MDs treating patients with rheumatic disease.  Understanding the African LHDIs reality is critical for the development of guidelines to improve care quality and outcomes. Table: Patterns of MTX prescription in Africa.  All values are % or median (range)

 

Total n=29

LHDI n=17

MHDI n=12

P value

Population (2015)

Rheumatologists/million

1,000,446,000

0.17 (0-9.4)

673,839,000

0.8 (0-0.66)

326,607,000

1.1 (0-9.4)

P=0.47

P=0.004

Rheumatologic indications for methotrexate

 Main reason RA (% reporting)

 Second reasons CTD/ PsA/ JIA

100

43/43/14

100

44/38/19

100

42/50/8

P=1

P=0.7

Pre-methotrexate evaluation

 Lung, liver, kidney, hematology

 Xray done

 TB screen CXR done

 HIV done

 Hepatitis B/C done

 Pregnancy screen by self-report only

97%

58%

62%

55%

52%

86%

94%

65%

71%

59%

41%

88%

100%

50%

50%

50%

67%

83%

P=1

P=0.4

P=0.3

P=0.6

P=0.3

P=1

Methotrexate prescription

 Starting dose (mg/wk)

 Maximum dose (mg/wk)

 Folate prescribed

10( 2.5-15)

25(12.5-30)

83%

10(7.5-15)

25(15-25)

82%

10(2.5-15)

22.5(12.5-30)

83%

P=0.5

P=0.5

P=1

Prescribing challenges

 Cost for 1 month (10-15 mg/wk) USD

 Injectable formulation available

 Inconsistent MTX supply

 MTX in hospital pharmacy

17( 0.5-27)

55%

66%

55%

17.25 (1-27)

52%

82%

35%

10(0.5-27)

58%

42%

83%

P=0.7

P=0.8

P=0.05

P=0.02

Adherence challenges

 Cost/drug availability

 Lack of prescribers

 Patient belief/education/intolerance

85%

15%

37%

94%

13%

44%

73%

18%

27%

P=0.3

P=1

P=0.4

 


Disclosure: C. A. Hitchon, None; Y. Liu, None; S. Shi, None; G. M. Mody, None; C. H. Feldman, None; M. Weinblatt, None; I. Colmegna, None.

To cite this abstract in AMA style:

Hitchon CA, Liu Y, Shi S, Mody GM, Feldman CH, Weinblatt M, Colmegna I. Patterns of Methotrexate Use in African Countries with Low Versus Medium/High Human Development Index: Preliminary Results of Semi-Structured Interviews [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/patterns-of-methotrexate-use-in-african-countries-with-low-versus-mediumhigh-human-development-index-preliminary-results-of-semi-structured-interviews/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/patterns-of-methotrexate-use-in-african-countries-with-low-versus-mediumhigh-human-development-index-preliminary-results-of-semi-structured-interviews/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology